Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC

TSK Mok; YL Wu; I Kudaba; DM Kowalski; BC Cho; HZ Turna; G de Castro; V Srimuninnimit; KK Laktionov; I Bondarenko; K Kubota; C Caglevic; B Karaszewska; T Dang; L Yin; J Penrod; G Lopes

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC

TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G de Castro, V Srimuninnimit, KK Laktionov, I Bondarenko, K Kubota, C Caglevic, B Karaszewska, T Dang, L Yin, J Penrod, G Lopes

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	38
Journal	Annals of Oncology
Volume	30
Issue number	Suppl.2
Publication status	Published - Apr 2019
Externally published	Yes
Event	European Lung Cancer Congress (ELCC) - Geneva, Switzerland Duration: 10 Apr 2019 → 13 Apr 2019

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this

Mok, TSK., Wu, YL., Kudaba, I., Kowalski, DM., Cho, BC., Turna, HZ., de Castro, G., Srimuninnimit, V., Laktionov, KK., Bondarenko, I., Kubota, K., Caglevic, C., Karaszewska, B., Dang, T., Yin, L., Penrod, J., & Lopes, G. (2019). Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC. Annals of Oncology, 30(Suppl.2), 38.

@article{1d7695f9d4f34cbbadd6b05229bff987,

title = "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC",

author = "TSK Mok and YL Wu and I Kudaba and DM Kowalski and BC Cho and HZ Turna and {de Castro}, G and V Srimuninnimit and KK Laktionov and I Bondarenko and K Kubota and C Caglevic and B Karaszewska and T Dang and L Yin and J Penrod and G Lopes",

year = "2019",

month = apr,

language = "English",

volume = "30",

pages = "38",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.2",

note = "European Lung Cancer Congress (ELCC) ; Conference date: 10-04-2019 Through 13-04-2019",

}

Mok, TSK, Wu, YL, Kudaba, I, Kowalski, DM, Cho, BC, Turna, HZ, de Castro, G, Srimuninnimit, V, Laktionov, KK, Bondarenko, I, Kubota, K, Caglevic, C, Karaszewska, B, Dang, T, Yin, L, Penrod, J & Lopes, G 2019, 'Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC', Annals of Oncology, vol. 30, no. Suppl.2, pp. 38.

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC. / Mok, TSK; Wu, YL; Kudaba, I et al.
In: Annals of Oncology, Vol. 30, No. Suppl.2, 04.2019, p. 38.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Final analysis of the phase III KEYNOTE-042 study

T2 - European Lung Cancer Congress (ELCC)

AU - Mok, TSK

AU - Wu, YL

AU - Kudaba, I

AU - Kowalski, DM

AU - Cho, BC

AU - Turna, HZ

AU - de Castro, G

AU - Srimuninnimit, V

AU - Laktionov, KK

AU - Bondarenko, I

AU - Kubota, K

AU - Caglevic, C

AU - Karaszewska, B

AU - Dang, T

AU - Yin, L

AU - Penrod, J

AU - Lopes, G

PY - 2019/4

Y1 - 2019/4

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000478089000101&DestLinkType=FullRecord&DestApp=WOS

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000478089000101

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

SP - 38

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.2

Y2 - 10 April 2019 through 13 April 2019

ER -

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC

Field of Science*

Publication Type*

Other files and links

Cite this